228 related articles for article (PubMed ID: 26684028)
21. Radiofrequency ablation for hepatocellular carcinoma induces glypican-3 peptide-specific cytotoxic T lymphocytes.
Nobuoka D; Motomura Y; Shirakawa H; Yoshikawa T; Kuronuma T; Takahashi M; Nakachi K; Ishii H; Furuse J; Gotohda N; Takahashi S; Nakagohri T; Konishi M; Kinoshita T; Komori H; Baba H; Fujiwara T; Nakatsura T
Int J Oncol; 2012 Jan; 40(1):63-70. PubMed ID: 21922136
[TBL] [Abstract][Full Text] [Related]
22. Anti-glypican-1 antibody-drug conjugate exhibits potent preclinical antitumor activity against glypican-1 positive uterine cervical cancer.
Matsuzaki S; Serada S; Hiramatsu K; Nojima S; Matsuzaki S; Ueda Y; Ohkawara T; Mabuchi S; Fujimoto M; Morii E; Yoshino K; Kimura T; Naka T
Int J Cancer; 2018 Mar; 142(5):1056-1066. PubMed ID: 29055044
[TBL] [Abstract][Full Text] [Related]
23. GPC3 DNA vaccine elicits potent cellular antitumor immunity against HCC in mice.
Li SQ; Lin J; Qi CY; Fu SJ; Xiao WK; Peng BG; Liang LJ
Hepatogastroenterology; 2014; 61(130):278-84. PubMed ID: 24901124
[TBL] [Abstract][Full Text] [Related]
24. Large-scale expansion of γδ T cells and peptide-specific cytotoxic T cells using zoledronate for adoptive immunotherapy.
Yoshikawa T; Takahara M; Tomiyama M; Nieda M; Maekawa R; Nakatsura T
Int J Oncol; 2014 Nov; 45(5):1847-56. PubMed ID: 25189159
[TBL] [Abstract][Full Text] [Related]
25. Selective elimination of undifferentiated human pluripotent stem cells using pluripotent state-specific immunogenic antigen Glypican-3.
Okada M; Tada Y; Seki T; Tohyama S; Fujita J; Suzuki T; Shimomura M; Ofuji K; Kishino Y; Nakajima K; Tanosaki S; Someya S; Kanazawa H; Senju S; Nakatsura T; Fukuda K
Biochem Biophys Res Commun; 2019 Apr; 511(3):711-717. PubMed ID: 30827508
[TBL] [Abstract][Full Text] [Related]
26. Long term complete response of advanced hepatocellular carcinoma to glypican-3 specific chimeric antigen receptor T-Cells plus sorafenib, a case report.
Sun H; Xing C; Jiang S; Yu K; Dai S; Kong H; Jin Y; Shan Y; Yang W; Wang Z; Xiao J; Wang H; Wang W; Li Z; Shi K
Front Immunol; 2022; 13():963031. PubMed ID: 36059488
[TBL] [Abstract][Full Text] [Related]
27. Non-clinical efficacy, safety and stable clinical cell processing of induced pluripotent stem cell-derived anti-glypican-3 chimeric antigen receptor-expressing natural killer/innate lymphoid cells.
Ueda T; Kumagai A; Iriguchi S; Yasui Y; Miyasaka T; Nakagoshi K; Nakane K; Saito K; Takahashi M; Sasaki A; Yoshida S; Takasu N; Seno H; Uemura Y; Tamada K; Nakatsura T; Kaneko S
Cancer Sci; 2020 May; 111(5):1478-1490. PubMed ID: 32133731
[TBL] [Abstract][Full Text] [Related]
28. Differential expression of glypican-3 (GPC3) in lung squamous cell carcinoma and lung adenocarcinoma and its clinical significance.
Yu X; Li Y; Chen SW; Shi Y; Xu F
Genet Mol Res; 2015 Aug; 14(3):10185-92. PubMed ID: 26345955
[TBL] [Abstract][Full Text] [Related]
29. Diverse solid tumors expressing a restricted epitope of L1-CAM can be targeted by chimeric antigen receptor redirected T lymphocytes.
Hong H; Stastny M; Brown C; Chang WC; Ostberg JR; Forman SJ; Jensen MC
J Immunother; 2014; 37(2):93-104. PubMed ID: 24509172
[TBL] [Abstract][Full Text] [Related]
30. Embryonic stem cell-derived dendritic cells expressing glypican-3, a recently identified oncofetal antigen, induce protective immunity against highly metastatic mouse melanoma, B16-F10.
Motomura Y; Senju S; Nakatsura T; Matsuyoshi H; Hirata S; Monji M; Komori H; Fukuma D; Baba H; Nishimura Y
Cancer Res; 2006 Feb; 66(4):2414-22. PubMed ID: 16489048
[TBL] [Abstract][Full Text] [Related]
31. [Expression of glypican-3 in lung squamous cell carcinoma and adenocarcinoma and its relation with prognosis].
Li H; Deng Q; Huang L; Tang H; Cheng X
Nan Fang Yi Ke Da Xue Xue Bao; 2013 Feb; 33(2):212-5. PubMed ID: 23443774
[TBL] [Abstract][Full Text] [Related]
32. A HLA-A2-restricted CTL epitope induces anti-tumor effects against human lung cancer in mouse xenograft model.
Sher YP; Lin SI; Chen IH; Liu HY; Lin CY; Chiang IP; Roffler S; Chen HW; Liu SJ
Oncotarget; 2016 Jan; 7(1):671-83. PubMed ID: 26621839
[TBL] [Abstract][Full Text] [Related]
33. 32A9, a novel human antibody for designing an immunotoxin and CAR-T cells against glypican-3 in hepatocellular carcinoma.
Liu X; Gao F; Jiang L; Jia M; Ao L; Lu M; Gou L; Ho M; Jia S; Chen F; Gao W
J Transl Med; 2020 Aug; 18(1):295. PubMed ID: 32746924
[TBL] [Abstract][Full Text] [Related]
34. HM1.24 (CD317) is a novel target against lung cancer for immunotherapy using anti-HM1.24 antibody.
Wang W; Nishioka Y; Ozaki S; Jalili A; Abe S; Kakiuchi S; Kishuku M; Minakuchi K; Matsumoto T; Sone S
Cancer Immunol Immunother; 2009 Jun; 58(6):967-76. PubMed ID: 18979097
[TBL] [Abstract][Full Text] [Related]
35. K562-Derived Whole-Cell Vaccine Enhances Antitumor Responses of CAR-Redirected Virus-Specific Cytotoxic T Lymphocytes In Vivo.
Caruana I; Weber G; Ballard BC; Wood MS; Savoldo B; Dotti G
Clin Cancer Res; 2015 Jul; 21(13):2952-62. PubMed ID: 25691731
[TBL] [Abstract][Full Text] [Related]
36. Antitumor efficacy of a human interleukin-12 expression plasmid demonstrated in a human peripheral blood leukocyte/human lung tumor xenograft SCID mouse model.
Hess SD; Egilmez NK; Shiroko J; Bankert RB
Cancer Gene Ther; 2001 May; 8(5):371-7. PubMed ID: 11477457
[TBL] [Abstract][Full Text] [Related]
37. CD271 is a negative prognostic factor and essential for cell proliferation in lung squamous cell carcinoma.
Mochizuki M; Nakamura M; Sibuya R; Okazaki T; Abe J; Nakagawa T; Takahashi S; Yamazaki T; Imai T; Takano A; Ito H; Yokose T; Miyagi Y; Daigo Y; Sato I; Satoh K; Sugamura K; Yamaguchi K; Tamai K
Lab Invest; 2019 Sep; 99(9):1349-1362. PubMed ID: 31019292
[TBL] [Abstract][Full Text] [Related]
38. Reduction of EGP-2-positive pulmonary metastases by bispecific-antibody-redirected T cells in an immunocompetent rat model.
Kroesen BJ; Helfrich W; Bakker A; Wubbena AS; Bakker H; Kal HB; The TH; de Leij L
Int J Cancer; 1995 Jun; 61(6):812-8. PubMed ID: 7790116
[TBL] [Abstract][Full Text] [Related]
39. Glypican-3 could be an effective target for immunotherapy combined with chemotherapy against ovarian clear cell carcinoma.
Suzuki S; Yoshikawa T; Hirosawa T; Shibata K; Kikkawa F; Akatsuka Y; Nakatsura T
Cancer Sci; 2011 Sep; 102(9):1622-9. PubMed ID: 21668581
[TBL] [Abstract][Full Text] [Related]
40. A novel tumor-associated antigen, cell division cycle 45-like can induce cytotoxic T-lymphocytes reactive to tumor cells.
Tomita Y; Imai K; Senju S; Irie A; Inoue M; Hayashida Y; Shiraishi K; Mori T; Daigo Y; Tsunoda T; Ito T; Nomori H; Nakamura Y; Kohrogi H; Nishimura Y
Cancer Sci; 2011 Apr; 102(4):697-705. PubMed ID: 21231984
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]